PharmaNet system dramatically reduced inappropriate prescriptions of potentially addictive drugs

A centralized prescription network providing real-time information to pharmacists in British Columbia, Canada, resulted in dramatic reductions in inappropriate prescriptions for opioid analgesics and benzodiazepines, widely used and potentially addictive drugs. The findings are reported in a study in CMAJ (Canadian Medical Association Journal).

The study found that PharmaNet, a real-time prescription system implemented in BC pharmacies in July 1995, reduced potentially inappropriate prescriptions for opioids and benzodiazepines in two groups of patients—those on social assistance and seniors. The reductions ranged from about one-third (33%) to one-half (49%) depending on the drug and patient group.

"Our study demonstrates that a system like PharmaNet can help reduce the potentially inappropriate prescribing of medications that are prone to misuse," said lead author Colin Dormuth of the Therapeutics Initiative at the University of British Columbia. "In the five-year period of our study, the reduction in inappropriate refills was dramatic and sustained after the implementation of PharmaNet."

The PharmaNet system allows BC pharmacists to view the most recent 14 months of a patient's medication use regardless of which physician prescribed the drugs or which pharmacy dispensed them. The system enables pharmacists to identify potentially harmful drug interactions, accidental duplications in therapy or potential prescription .

Researchers tracked "potentially inappropriate" prescriptions for opioids and benzodiazepines in BC, defined as a second prescription for the same drug issued by a different doctor and a different pharmacy within 7 days of a previous prescription for at least 30 tablets.

Benzodiazepines and are that are prone to misuse and addiction in some patients. Benzodiazepines include sedatives and anti-anxiety drugs such as diazepam, lorazepam and others, whereas are taken for pain relief and include morphine, codeine, oxycodone and other drugs.

Most provinces have now adopted either a system allowing the to view a patient's up-to-date medication history at the time of dispensing a medication or a real-time monitoring program specifically aimed at monitoring prescription drugs prone to misuse. Ontario adopted the latter approach in establishing its Narcotics Monitoring System earlier this year.

"Centralized drug information systems and monitoring programs are critical to help ensure these medications are used appropriately," observes coauthor David Juurlink, Head of Clinical Pharmacology and Toxicology at Toronto's Sunnybrook Health Sciences Centre and a scientist at the Institute for Clinical and Evaluative Sciences (ICES).

The study covered the period from Jan. 1, 1993 to Dec. 31, 1997—the 5-year period flanking the program's implementation. Because comprehensive data was available for people aged 65 years and over and patients receiving social assistance, the study focused on these two groups of patients.

More information: www.cmaj.ca/lookup/doi/10.1503/cmaj.120465

add to favorites email to friend print save as pdf

Related Stories

Opioids linked to higher risk of pneumonia in older adults

Sep 22, 2011

Opioids -- a class of medicines commonly given for pain -- were associated with a higher risk of pneumonia in a study of 3,061 adults, aged 65 to 94, e-published in advance of publication in the Journal of the American Ge ...

Recommended for you

Ebola vaccine not before late 2016: GSK researcher

Oct 17, 2014

An Ebola vaccine by British pharmaceuticals giant GlaxoSmithKline may not be ready for commercial use until late 2016 and should therefore not be seen as the "primary answer" to the current outbreak, a company researcher ...

Chimerix gets FDA OK to test drug for Ebola

Oct 17, 2014

(AP)—A North Carolina drugmaker plans to test its experimental antiviral drug in patients who have Ebola, after getting authorization from regulators at the Food and Drug Administration.

Esbriet, ofev approved to treat deadly lung disease

Oct 16, 2014

(HealthDay)—Two new drugs have been approved by the U.S. Food and Drug Administration to treat progressive lung scarring from an uncertain cause, medically called idiopathic pulmonary fibrosis (IPF).

FDA weighs removing bolded warning from Chantix

Oct 14, 2014

(AP)—The Food and Drug Administration will ask a panel of experts later this week whether a bold-letter warning on the anti-smoking drug Chantix should be removed based on company-supported evidence that the drug does not ...

Drug-coated balloon catheter approved

Oct 13, 2014

(HealthDay)—The first drug-coated balloon catheter designed to clear narrowed or blocked arteries in the thigh and knee has been approved by the U.S. Food and Drug Administration.

User comments